REFERÊNCIAS CONSULTADAS: 1. Bula do produto: Doril Enxaqueca. 2. Diener HC, et al. The efficacy and tolerability of a fixed combination of acetylsalicylic acid, paracetamol, and caffeine in patients with severe headache: a post-hoc subgroup analysis from a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia. 2011,31(14):1466-76. Doril. Comprimido. ácido acetilsalicílico 500mg, cafeína 30mg. Indicações: analgésico e antitérmico. MS 1.7817.0007. Cosmed Indústria de Cosméticos e Medicamentos S.A. Doril Enxaqueca. Comprimido revestido. paracetamol 250mg, ácido acetilsalicílico 250mg, cafeína 65mg. Indicações: alívio de dores leves a moderadas e enxaquecas. MS 1.7817.0123. Cosmed Indústria de Cosméticos e Medicamentos S.A. Doril DC 500. Comprimido. dipirona 500mg e cafeína 65mg. Indicações: analgésico especialmente para o tratamento de dores de cabeça e enxaqueca. MS 1.7817.0859. Cosmed Indústria de Cosméticos e Medicamentos S.A. Outubro/2020
*O som da dor é uma produção publicitária inspirada em estudos científicos1-15.
Referências Bibliográficas: 1.Queiroz LP, et al. A nationwide population-based study of migraine in Brazil. Cephalalgia. 2009;29(6):642-9.2.Queiroz LP, et al. Chronic daily headache in Brazil: a nationwide population-based study. Cephalalgia. 2008;28(12):1264-9.3.Karsan N, Goadsby PJ. Biological insights from the premonitory symptoms of migraine. Nat Rev Neurol. 2018;14(12):699-710.4.Peres MFP, et al. Migraine: a major debilitating chronic non-communicable disease in Brazil, evidence from two national surveys. J Headache Pain. 2019; 20(1):85.5.Pietrobon D, Striessnig J. Neurobiology of migraine. Nat Rev Neurosci. 2003;4(5):386-98.6.Goadsby PJ, et al. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017;97(2):553-622.7.GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954-976. 8.Souza MNP, et al. A survey assessing the burden and impact of migraine across 6 countries in South America, Asia and Australia. Migraine Trust Virtual 2020 - Digital presentations. Cephalalgia. 2020;40(1S):18-110. 9.Lopes N, et al. PND133 - Living with migraine: the impact on Brazilian patients lives from my migraine voice survey. Value in Health. 2018; 21(S3): S351.10.Sutherland HG, et al. Advances in genetics of migraine. J Headache Pain. 2019;20(1):72.11.Schulte LH, May A. The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks. Brain. 2016;139(Pt 7):1987-93.12.Leao AAP. Spreading depression of activity in the cerebral cortex. J Neurophysiol. 1944;7:359–390.13.Oliveira AB, et al. Annual indirect costs secondary to headache disability in Brazil. Cephalalgia. 2020;40(6):597-605.14. Dodick DW, et al. Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache. 2016;56(5):821-834.15.Reis Neto JP, Busch JM. PND35 - Estimate of the impact and costs of migraine from an health plan in Brazil: real world scenario study. Value in Health. 2019; 22 (S2):S276. 16.Bula do Produto Doril Enxaqueca.
Abril/2021
